🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07478341
Recruiting Not applicable

Hybrid Breastfeeding Education in Late Pregnancy: Effects on Antenatal Attachment and Breastfeeding

NCT07478341 · tracked via the Priya Life Science Turkey tracker
Sponsor
Emel GÜÇLÜ CİHAN
Phase
Not applicable
Started
2026-01-30
Last updated
2026-08-26

Condition(s) studied

Breast FeedingExclusive Breast FeedingMaternal-Fetal AttachmentPrimiparity

Investigational drug(s) / intervention(s)

Individualized Hybrid Breastfeeding Education

Individualized Hybrid Breastfeeding Education: Primiparous pregnant women in the intervention group will receive an individualized hybrid breastfeeding education program planned for late pregnancy. The education consists of a hybrid structure including face-to-face sessions and online educational materials. The content covers the importance of breastfeeding, breastfeeding techniques, common breastfeeding problems, approaches to support mother-infant attachment, and preparation for the postpartum breastfeeding process. The intervention will be provided in addition to standard prenatal care.

Study summary

This randomized controlled study aims to examine the effect of individualized hybrid breastfeeding education provided during late pregnancy on antenatal attachment and breastfeeding behaviors among first-time mothers. Participants will be randomly assigned to either the intervention or control group. Women in the intervention group will receive individualized hybrid breastfeeding education beginning at the 36th week of pregnancy. The program includes a face-to-face individual breastfeeding education session at 36 weeks of pregnancy and a reinforcement and practice session at 38 weeks. Participants will also have access to personalized digital educational materials, short educational videos, and online consultation support. In the postpartum period, participants will receive an online support session during the first week after birth and a follow-up session through online communication or telephone at the sixth postpartum week. The control group will receive routine hospital education during pregnancy. After completion of the study, the same educational materials will be provided to the control group in accordance with ethical principles. Data will be collected using the Demographic Information Form, Breastfeeding Behavior Evaluation Form, Antenatal Attachment Inventory, and Breastfeeding Self-Efficacy Scale. Written informed consent will be obtained from all participants prior to enrollment.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: Aged 18-35 years, At 36 weeks of gestation or later, Experiencing their first pregnancy (primiparous), Having a singleton pregnancy, Able to read and write in Turkish and capable of communication, Having access to a smartphone or the internet, Free from any physical or mental health problems that would prevent participation in the education, Willing to voluntarily participate in the study and provide written informed consent. Exclusion Criteria: Presence of chronic physical illness or pregnancy complications (e.g., preeclampsia, gestational diabetes), Multiple pregnancy, Gestation earlier than 36 weeks, Inability to actively participate in the education due to communication barriers or cognitive impairment, Lack of access to a smartphone or the internet, Failure to attend any stage of the educational program or voluntary withdrawal from the study, Refusal to participate in the study or failure to sign the informed consent form.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Elbistan Devlet Hastanesi Elbistan Kahramanmaraş Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07478341 on ClinicalTrials.gov ↗ ← All trials in Turkey